Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
- 14 November 2005
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 8 (2) , 155-162
- https://doi.org/10.1002/jgm.849
Abstract
Background Viruses are being exploited as vectors to deliver therapeutic genetic information into target cells. The success of this approach will depend on the ability to overcome current limitations, especially in terms of safety and efficiency, through molecular engineering of the viral particles. Methods Here we show that in vitro directed evolution can be successfully performed to randomize the viral capsid by error prone PCR and to obtain mutants with improved phenotype. Results To demonstrate the potential of this technology we selected several adeno‐associated virus (AAV) capsid variants that are less efficiently neutralized by human antibodies. These mutations can be used to generate novel vectors for the treatment of patients with pre‐existing immunity to AAV. Conclusions Our results demonstrate that combinatorial engineering overcomes the limitations of rational design approaches posed by incomplete understanding of the infectious process and at the same time offers a powerful tool to dissect basic viral biology by reverse genetics. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 30 references indexed in Scilit:
- Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodiesGene Therapy, 2003
- In vitro selection of viral vectors with modified tropism: the adeno-associated virus displayMolecular Therapy, 2003
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface ReceptorsHuman Gene Therapy, 2001
- Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial CellsMolecular Therapy, 2001
- Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus CapsidsMolecular Therapy, 2001
- Directed evolution of proteins by exon shufflingNature Biotechnology, 2001
- Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus VectorsMolecular Therapy, 2000
- Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2Gene Therapy, 1999
- Improved Green Fluorescent Protein by Molecular Evolution Using DNA ShufflingNature Biotechnology, 1996